ANI PHARMACEUTICALS, INC Research and Development Expense
ANI PHARMACEUTICALS, INC (ANIP) reported Research and Development Expense of $14.75 million for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-07.
Financial Statements › Expense Statement › Operating Expenses
us-gaap:ResearchAndDevelopmentExpense · last filed 2026-08-07
- ANI PHARMACEUTICALS, INC research and development expense for the quarter ending 2026-06-30 was $14.75M, a 10.81% decline year-over-year.
- ANI PHARMACEUTICALS, INC research and development expense for the quarter ending 2026-03-31 was $10.60M, a 0.34% increase year-over-year.
- ANI PHARMACEUTICALS, INC research and development expense for the quarter ending 2025-12-31 was $12.26M, a 26.34% decline year-over-year.
- ANI PHARMACEUTICALS, INC research and development expense for the quarter ending 2025-09-30 was $12.30M, a 21.48% increase year-over-year.
- ANI PHARMACEUTICALS, INC research and development expense for fiscal 2025 was $51.66M, a 15.89% increase from fiscal 2024.
- ANI PHARMACEUTICALS, INC research and development expense for fiscal 2024 was $44.58M, a 30.03% increase from fiscal 2023.
- ANI PHARMACEUTICALS, INC research and development expense for fiscal 2023 was $34.29M, a 53.62% increase from fiscal 2022.
- ANI PHARMACEUTICALS, INC research and development expense for fiscal 2022 was $22.32M, a 96.31% increase from fiscal 2021.
| Period end | Research and Development Expense 3 month | Research and Development Expense 3 month as first filed | Research and Development Expense 6 month | Research and Development Expense 6 month as first filed | Research and Development Expense 9 month | Research and Development Expense 9 month as first filed | Research and Development Expense 12 month | Research and Development Expense 12 month as first filed |
|---|---|---|---|---|---|---|---|---|
| 2026-06-30 | $14.75M 10-Q · filed 2026-08-07 | $25.35M 10-Q · filed 2026-08-07 | $37.61M derived: sum of 3 quarters · filed 2026-08-07 | $49.91M derived: sum of 4 quarters · filed 2026-08-07 | ||||
| 2026-03-31 | $10.60M 10-Q · filed 2026-05-08 | $22.86M derived: sum of 2 quarters · filed 2026-05-08 | $35.16M derived: sum of 3 quarters · filed 2026-05-08 | $51.70M derived: sum of 4 quarters · filed 2026-08-07 | ||||
| 2025-12-31 | $12.26M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-27 | $24.57M derived: sum of 2 quarters · filed 2026-02-27 | $41.10M derived: sum of 3 quarters · filed 2026-08-07 | $51.66M 10-K · filed 2026-02-27 | ||||
| 2025-09-30 | $12.30M 10-Q · filed 2025-11-07 | $28.84M derived: sum of 2 quarters · filed 2026-08-07 | $39.40M 10-Q · filed 2025-11-07 | $56.05M derived: sum of 4 quarters · filed 2026-08-07 | ||||
| 2025-06-30 | $16.54M 10-Q · filed 2026-08-07 | $27.10M 10-Q · filed 2026-08-07 | $43.74M derived: sum of 3 quarters · filed 2026-08-07 | $53.87M derived: sum of 4 quarters · filed 2026-08-07 | ||||
| 2025-03-31 | $10.56M 10-Q · filed 2026-05-08 | $27.21M derived: sum of 2 quarters · filed 2026-05-08 | $37.34M derived: sum of 3 quarters · filed 2026-05-08 | $44.63M derived: sum of 4 quarters · filed 2026-05-08 | ||||
| 2024-12-31 | $16.65M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-27 | $26.77M derived: sum of 2 quarters · filed 2026-02-27 | $34.07M derived: sum of 3 quarters · filed 2026-02-27 | $44.58M 10-K · filed 2026-02-27 | ||||
| 2024-09-30 | $10.13M 10-Q · filed 2025-11-07 | $17.42M derived: sum of 2 quarters · filed 2025-11-07 | $27.93M 10-Q · filed 2025-11-07 | $37.80M derived: sum of 4 quarters · filed 2026-02-27 | ||||
| 2024-06-30 | $7.30M 10-Q · filed 2025-08-08 | $17.81M 10-Q · filed 2025-08-08 | $27.67M derived: sum of 3 quarters · filed 2026-02-27 | $38.80M derived: sum of 4 quarters · filed 2026-02-27 | ||||
| 2024-03-31 | $10.51M 10-Q · filed 2025-05-09 | $20.38M derived: sum of 2 quarters · filed 2026-02-27 | $31.50M derived: sum of 3 quarters · filed 2026-02-27 | $38.87M derived: sum of 4 quarters · filed 2026-02-27 | ||||
| 2023-12-31 | $9.87M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-27 | $20.99M derived: sum of 2 quarters · filed 2026-02-27 | $28.36M derived: sum of 3 quarters · filed 2026-02-27 | $34.29M 10-K · filed 2026-02-27 | ||||
| 2023-09-30 | $11.12M 10-Q · filed 2024-11-08 | $18.50M derived: sum of 2 quarters · filed 2024-11-08 | $24.42M 10-Q · filed 2024-11-08 | $29.64M derived: sum of 4 quarters · filed 2025-02-28 | ||||
| 2023-06-30 | $7.37M 10-Q · filed 2024-08-06 | $13.30M 10-Q · filed 2024-08-06 | $18.52M derived: sum of 3 quarters · filed 2025-02-28 | $26.18M derived: sum of 4 quarters · filed 2025-02-28 | ||||
| 2023-03-31 | $5.92M 10-Q · filed 2024-05-10 | $11.15M derived: sum of 2 quarters · filed 2025-02-28 | $18.80M derived: sum of 3 quarters · filed 2025-02-28 | $22.97M derived: sum of 4 quarters · filed 2025-02-28 | ||||
| 2022-12-31 | $5.22M derived: 10-K 12 month − 10-Q 9 month · filed 2025-02-28 | $12.88M derived: sum of 2 quarters · filed 2025-02-28 | $17.04M derived: sum of 3 quarters · filed 2025-02-28 | $22.32M 10-K · filed 2025-02-28 | ||||
| 2022-09-30 | $7.66M 10-Q · filed 2023-11-08 | $11.82M derived: sum of 2 quarters · filed 2023-11-08 | $17.10M 10-Q · filed 2023-11-08 | $20.24M derived: sum of 4 quarters · filed 2024-02-29 | ||||
| 2022-06-30 | $4.17M 10-Q · filed 2023-08-09 | $9.44M 10-Q · filed 2023-08-09 | $12.58M derived: sum of 3 quarters · filed 2024-02-29 | $15.04M derived: sum of 4 quarters · filed 2024-02-29 | ||||
| 2022-03-31 | $5.27M 10-Q · filed 2023-05-08 | $8.41M derived: sum of 2 quarters · filed 2024-02-29 | $10.87M derived: sum of 3 quarters · filed 2024-02-29 | $13.68M derived: sum of 4 quarters · filed 2024-02-29 | ||||
| 2021-12-31 | $3.14M derived: 10-K 12 month − 10-Q 9 month · filed 2024-02-29 | $5.60M derived: sum of 2 quarters · filed 2024-02-29 | $8.40M derived: sum of 3 quarters · filed 2024-02-29 | $11.37M 10-K · filed 2024-02-29 | ||||
| 2021-09-30 | $2.46M 10-Q · filed 2022-11-09 | $5.26M derived: sum of 2 quarters · filed 2022-11-09 | $8.23M 10-Q · filed 2022-11-09 | $11.91M derived: sum of 4 quarters · filed 2023-03-09 | ||||
| 2021-06-30 | $2.81M 10-Q · filed 2022-08-08 | $5.77M 10-Q · filed 2022-08-08 | $9.46M derived: sum of 3 quarters · filed 2023-03-09 | $12.39M derived: sum of 4 quarters · filed 2023-03-09 | ||||
| 2021-03-31 | $2.97M 10-Q · filed 2022-05-10 | $6.65M derived: sum of 2 quarters · filed 2023-03-09 | $9.59M derived: sum of 3 quarters · filed 2023-03-09 | $12.63M derived: sum of 4 quarters · filed 2023-03-09 | ||||
| 2020-12-31 | $3.68M derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-09 | $6.62M derived: sum of 2 quarters · filed 2023-03-09 | $9.66M derived: sum of 3 quarters · filed 2023-03-09 | $16.00M 10-K · filed 2023-03-09 | ||||
| 2020-09-30 | $2.94M 10-Q · filed 2021-11-01 | $5.97M derived: sum of 2 quarters · filed 2021-11-01 | $12.32M 10-Q · filed 2021-11-01 | $17.00M derived: sum of 4 quarters · filed 2022-03-15 | ||||
| 2020-06-30 | $3.04M 10-Q · filed 2021-08-06 | $9.38M 10-Q · filed 2021-08-06 | $14.06M derived: sum of 3 quarters · filed 2022-03-15 | $19.04M derived: sum of 4 quarters · filed 2022-03-15 | ||||
| 2020-03-31 | $6.34M 10-Q · filed 2021-05-07 | $11.02M derived: sum of 2 quarters · filed 2022-03-15 | $16.00M derived: sum of 3 quarters · filed 2022-03-15 | $21.78M derived: sum of 4 quarters · filed 2022-03-15 | ||||
| 2019-12-31 | $4.68M derived: 10-K 12 month − 10-Q 9 month · filed 2022-03-15 | $9.66M derived: sum of 2 quarters · filed 2022-03-15 | $15.43M derived: sum of 3 quarters · filed 2022-03-15 | $19.81M 10-K · filed 2022-03-15 | ||||
| 2019-09-30 | $4.98M 10-Q · filed 2020-11-05 | $10.76M derived: sum of 2 quarters · filed 2020-11-05 | $15.13M 10-Q · filed 2020-11-05 | $18.61M derived: sum of 4 quarters · filed 2021-03-11 | ||||
| 2019-06-30 | $5.77M 10-Q · filed 2020-08-06 | $10.15M 10-Q · filed 2020-08-06 | $13.63M derived: sum of 3 quarters · filed 2021-03-11 | $18.30M derived: sum of 4 quarters · filed 2021-03-11 | ||||
| 2019-03-31 | $4.37M 10-Q · filed 2020-05-07 | $7.86M derived: sum of 2 quarters · filed 2021-03-11 | $12.52M derived: sum of 3 quarters · filed 2021-03-11 | $17.66M derived: sum of 4 quarters · filed 2021-03-11 | ||||
| 2018-12-31 | $3.48M derived: 10-K 12 month − 10-Q 9 month · filed 2021-03-11 | $8.15M derived: sum of 2 quarters · filed 2021-03-11 | $13.29M derived: sum of 3 quarters · filed 2021-03-11 | $15.39M 10-K · filed 2021-03-11 | ||||
| 2018-09-30 | $4.67M 10-Q · filed 2019-11-06 | $9.80M derived: sum of 2 quarters · filed 2019-11-06 | $11.91M 10-Q · filed 2019-11-06 | $14.56M derived: sum of 4 quarters · filed 2020-02-27 | ||||
| 2018-06-30 | $5.14M 10-Q · filed 2019-08-07 | $7.24M 10-Q · filed 2019-08-07 | $9.89M derived: sum of 3 quarters · filed 2020-02-27 | $12.52M derived: sum of 4 quarters · filed 2020-02-27 | ||||
| 2018-03-31 | $2.10M 10-Q · filed 2019-05-09 | $4.75M derived: sum of 2 quarters · filed 2020-02-27 | $7.39M derived: sum of 3 quarters · filed 2020-02-27 | $9.55M derived: sum of 4 quarters · filed 2020-02-27 | ||||
| 2017-12-31 | $2.65M derived: 10-K 12 month − 10-Q 9 month · filed 2020-02-27 | $5.29M derived: sum of 2 quarters · filed 2020-02-27 | $7.45M derived: sum of 3 quarters · filed 2020-02-27 | $9.07M 10-K · filed 2020-02-27 | ||||
| 2017-09-30 | $2.63M 10-Q · filed 2018-11-06 | $4.80M derived: sum of 2 quarters · filed 2018-11-06 | $6.42M 10-Q · filed 2018-11-06 | $6.55M derived: sum of 4 quarters · filed 2019-02-27 | ||||
| 2017-06-30 | $2.17M 10-Q · filed 2017-08-03 | $3.79M 10-Q · filed 2018-08-07 | $3.92M derived: sum of 3 quarters · filed 2019-02-27 | $4.96M derived: sum of 4 quarters · filed 2019-02-27 | ||||
| 2017-03-31 | $1.62M 10-Q · filed 2018-05-08 | $1.75M derived: sum of 2 quarters · filed 2019-02-27 | $2.79M derived: sum of 3 quarters · filed 2019-02-27 | $3.56M derived: sum of 4 quarters · filed 2019-02-27 | ||||
| 2016-12-31 | $135.00K derived: 10-K 12 month − 10-Q 9 month · filed 2019-02-27 | $1.18M derived: sum of 2 quarters · filed 2019-02-27 | $1.94M derived: sum of 3 quarters · filed 2019-02-27 | $2.91M 10-K · filed 2019-02-27 | ||||
| 2016-09-30 | $1.04M 10-Q · filed 2017-11-02 | $1.80M derived: sum of 2 quarters · filed 2017-11-02 | $2.77M 10-Q · filed 2017-11-02 | $3.43M derived: sum of 4 quarters · filed 2018-02-27 | ||||
| 2016-06-30 | $764.00K 10-Q · filed 2017-08-03 | $1.73M 10-Q · filed 2017-08-03 | $2.39M derived: sum of 3 quarters · filed 2018-02-27 | $3.21M derived: sum of 4 quarters · filed 2018-02-27 | ||||
| 2016-03-31 | $966.00K 10-Q · filed 2017-05-04 | $1.63M derived: sum of 2 quarters · filed 2018-02-27 | $2.44M derived: sum of 3 quarters · filed 2018-02-27 | $3.44M derived: sum of 4 quarters · filed 2018-02-27 | ||||
| 2015-12-31 | $661.00K derived: 10-K 12 month − 10-Q 9 month · filed 2018-02-27 | $1.48M derived: sum of 2 quarters · filed 2018-02-27 | $2.47M derived: sum of 3 quarters · filed 2018-02-27 | $2.87M 10-K · filed 2018-02-27 | ||||
| 2015-09-30 | $815.00K 10-Q · filed 2016-11-03 | $1.81M derived: sum of 2 quarters · filed 2016-11-03 | $2.21M 10-Q · filed 2016-11-03 | $2.78M derived: sum of 4 quarters · filed 2017-03-02 | ||||
| 2015-06-30 | $995.00K 10-Q · filed 2016-08-04 | $1.40M 10-Q · filed 2016-08-04 | $1.97M derived: sum of 3 quarters · filed 2017-03-02 | $2.85M derived: sum of 4 quarters · filed 2017-03-02 | ||||
| 2015-03-31 | $403.00K 10-Q · filed 2016-05-05 | $971.00K derived: sum of 2 quarters · filed 2017-03-02 | $1.85M derived: sum of 3 quarters · filed 2017-03-02 | $2.71M derived: sum of 4 quarters · filed 2017-03-02 | ||||
| 2014-12-31 | $568.00K derived: 10-K 12 month − 10-Q 9 month · filed 2017-03-02 | $1.45M derived: sum of 2 quarters · filed 2017-03-02 | $2.30M derived: sum of 3 quarters · filed 2017-03-02 | $2.68M 10-K · filed 2017-03-02 | ||||
| 2014-09-30 | $883.00K 10-Q · filed 2015-11-03 | $1.73M derived: sum of 2 quarters · filed 2015-11-03 | $2.11M 10-Q · filed 2015-11-03 | $2.63M derived: sum of 4 quarters · filed 2016-02-23 | ||||
| 2014-06-30 | $851.00K 10-Q · filed 2015-08-04 | $1.23M 10-Q · filed 2015-08-04 | $1.75M derived: sum of 3 quarters · filed 2016-02-23 | $2.21M derived: sum of 4 quarters · filed 2016-02-23 | ||||
| 2014-03-31 | $376.00K 10-Q · filed 2015-05-05 | $900.00K derived: sum of 2 quarters · filed 2016-02-23 | $1.35M derived: sum of 3 quarters · filed 2016-02-23 | $1.79M derived: sum of 4 quarters · filed 2016-02-23 | ||||
| 2013-12-31 | $524.00K derived: 10-K 12 month − 10-Q 9 month · filed 2016-02-23 | $978.00K derived: sum of 2 quarters · filed 2016-02-23 | $1.42M derived: sum of 3 quarters · filed 2016-02-23 | $1.71M 10-K · filed 2016-02-23 | ||||
| 2013-09-30 | $454.00K 10-Q · filed 2014-11-10 | $453.90K 10-Q · filed 2013-11-07 | $891.00K derived: sum of 2 quarters · filed 2014-11-10 | $1.19M 10-Q · filed 2014-11-10 | $1.19M 10-Q · filed 2013-11-07 | $3.70M derived: sum of 4 quarters · filed 2014-11-10 | ||
| 2013-06-30 | $437.00K 10-Q · filed 2014-08-07 | $437.18K 10-Q · filed 2013-08-09 | $733.00K 10-Q · filed 2014-08-07 | $733.56K 10-Q · filed 2013-08-09 | $3.25M derived: sum of 3 quarters · filed 2014-08-07 | $3.40M derived: sum of 4 quarters · filed 2014-08-07 | ||
| 2013-03-31 | $296.00K 10-Q · filed 2014-05-12 | $972.05K 10-Q · filed 2013-05-10 | $2.81M derived: sum of 2 quarters · filed 2014-05-12 | $2.96M derived: sum of 3 quarters · filed 2014-05-12 | $3.17M derived: sum of 4 quarters · filed 2014-05-12 | |||
| 2012-12-31 | $2.51M 10-K · filed 2013-02-28 | $2.66M derived: sum of 2 quarters · filed 2013-11-07 | $2.87M derived: sum of 3 quarters · filed 2013-11-07 | $1.16M 10-K · filed 2014-02-28 | $16.89M 10-K · filed 2013-02-28 | |||
| 2012-09-30 | $148.65K 10-Q · filed 2013-11-07 | $3.87M 10-Q · filed 2012-11-08 | $358.52K derived: sum of 2 quarters · filed 2013-11-07 | $636.73K 10-Q · filed 2013-11-07 | $14.45M 10-Q · filed 2012-11-08 | $12.24M derived: sum of 4 quarters · filed 2013-11-07 | ||
| 2012-06-30 | $209.88K 10-Q · filed 2013-08-09 | $5.40M 10-Q · filed 2012-08-01 | $488.08K 10-Q · filed 2013-08-09 | $10.58M 10-Q · filed 2012-08-01 | $12.09M derived: sum of 3 quarters · filed 2013-08-09 | $23.59M derived: sum of 4 quarters · filed 2013-08-09 | ||
| 2012-03-31 | $5.18M 10-Q · filed 2013-05-10 | $11.88M derived: sum of 2 quarters · filed 2013-05-10 | $23.38M derived: sum of 3 quarters · filed 2013-05-10 | $34.50M derived: sum of 4 quarters · filed 2013-05-10 | ||||
| 2011-12-31 | $6.70M 10-K · filed 2013-02-28 | $18.20M derived: sum of 2 quarters · filed 2013-02-28 | $29.32M derived: sum of 3 quarters · filed 2013-02-28 | $44.18M 10-K · filed 2013-02-28 | ||||
| 2011-09-30 | $11.50M 10-K · filed 2013-02-28 | $22.62M derived: sum of 2 quarters · filed 2013-02-28 | $37.48M 10-Q · filed 2012-11-08 | $49.39M derived: sum of 4 quarters · filed 2013-02-28 | ||||
| 2011-06-30 | $11.12M 10-K · filed 2013-02-28 | $25.98M 10-Q · filed 2012-08-01 | $37.89M derived: sum of 3 quarters · filed 2013-02-28 | $47.60M derived: sum of 4 quarters · filed 2013-02-28 | ||||
| 2011-03-31 | $14.86M 10-K · filed 2013-02-28 | $26.77M derived: sum of 2 quarters · filed 2013-02-28 | $36.49M derived: sum of 3 quarters · filed 2013-02-28 | $45.14M derived: sum of 4 quarters · filed 2013-02-28 | ||||
| 2010-12-31 | $11.90M 8-K · filed 2013-01-28 | $21.62M derived: sum of 2 quarters · filed 2013-01-28 | $30.28M derived: sum of 3 quarters · filed 2013-01-28 | $39.71M 10-K · filed 2013-02-28 | ||||
| 2010-09-30 | $9.72M 8-K · filed 2013-01-28 | $18.37M derived: sum of 2 quarters · filed 2013-01-28 | $27.80M 10-Q · filed 2011-11-09 | |||||
| 2010-06-30 | $8.66M 8-K · filed 2013-01-28 | $18.08M 10-Q · filed 2011-08-05 | ||||||
| 2010-03-31 | $9.43M 8-K · filed 2013-01-28 | |||||||
| 2009-12-31 | $13.68M 8-K · filed 2013-01-28 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| COMPASS Pathways plc (CMPS) | $1.812B | -4.87 | |
| Septerna, Inc. (SEPN) | United States | $1.783B | -63.01 |
| Xencor Inc (XNCR) | United States | $1.776B | -7.33 |
| Zymeworks Inc. (ZYME) | United States | $1.902B | -12.44 |
| Eton Pharmaceuticals, Inc. (ETON) | United States | $1.701B | 80.74 |
| Sarepta Therapeutics, Inc. (SRPT) | United States | $1.941B | -13.89 |
| AGIOS PHARMACEUTICALS, INC. (AGIO) | United States | $1.962B | -5.38 |
| Xeris Biopharma Holdings, Inc. (XERS) | United States | $1.632B | -80.10 |
| Stoke Therapeutics, Inc. (STOK) | United States | $1.630B | -9.82 |
| Biohaven Ltd. (BHVN) | United States | $1.990B | -3.83 |